folder

Berlin Registry of Neuroimmunological entities (BERLimmun): protocol of a prospective observational study

Authors

  • P.S. Sperber
  • A.U. Brandt
  • H.G. Zimmermann
  • L.S. Bahr
  • C. Chien
  • S. Rekers
  • A. Mähler
  • C. Böttcher
  • S. Asseyer
  • A.S. Duchow
  • J. Bellmann-Strobl
  • K. Ruprecht
  • F. Paul
  • T. Schmitz-Hübsch

Journal

  • BMC Neurology

Citation

  • BMC Neurol 22 (1): 479

Abstract

  • BACKGROUND: Large-scale disease overarching longitudinal data are rare in the field of neuroimmunology. However, such data could aid early disease stratification, understanding disease etiology and ultimately improve treatment decisions. The Berlin Registry of Neuroimmunological Entities (BERLimmun) is a longitudinal prospective observational study, which aims to identify diagnostic, disease activity and prognostic markers and to elucidate the underlying pathobiology of neuroimmunological diseases. METHODS: BERLimmun is a single-center prospective observational study of planned 650 patients with neuroimmunological disease entity (e.g. but not confined to: multiple sclerosis, isolated syndromes, neuromyelitis optica spectrum disorders) and 85 healthy participants with 15 years of follow-up. The protocol comprises annual in-person visits with multimodal standardized assessments of medical history, rater-based disability staging, patient-report of lifestyle, diet, general health and disease specific symptoms, tests of motor, cognitive and visual functions, structural imaging of the neuroaxis and retina and extensive sampling of biological specimen. DISCUSSION: The BERLimmun database allows to investigate multiple key aspects of neuroimmunological diseases, such as immunological differences between diagnoses or compared to healthy participants, interrelations between findings of functional impairment and structural change, trajectories of change for different biomarkers over time and, importantly, to study determinants of the long-term disease course. BERLimmun opens an opportunity to a better understanding and distinction of neuroimmunological diseases.


DOI

doi:10.1186/s12883-022-02986-7